Press

Virexon Biodyne Announces Breakthrough mRNA Vaccine for Ich in Ornamental Goldfish

Whitehouse, NJ — Virexon Biodyne today announced pre-clinical success of its Aquagen-mRNA-13 platform, the world’s first messenger-RNA vaccine targeting Ichthyophthirius multifiliis (“Ich”), a pervasive protozoan infection in ornamental and laboratory goldfish.

Developed by the company’s Biomedical Systems Division, the vaccine utilizes Cold-Water Lipid Encapsulation for stable RNA delivery under aquatic temperature conditions. Aquagen-mRNA-13 is administered via intramuscular micro-injection, ensuring precise dosage and controlled antigen expression within piscine epidermal cells.

Each retail package includes:

• Two sterile 0.3 mL pre-filled syringes (single-fish use)

• Step-by-step illustrated injection guide

• Disposable aquatic handling gloves

• A Virexon Biodyne authenticity hologram for traceability

“Responsible aquarists understand that preventive bio-innovation is the foundation of ornamental wellness,” said Dr. Leah Moritz, Senior Director of Aquatic Translational Research. “Aquagen-mRNA-13 represents the future of precision immunology — even beneath the surface.”

Field trials conducted in partnership with certified ornamental aquaculture facilities across North America have shown a 94 % reduction in visible cyst formation and zero adverse behavioral outcomes over a 30-day observation period